Revolution Medicines and Summit Therapeutics announce a clinical collaboration to evaluate RAS inhibitors combined with ivonescimab in cancer treatments.
Quiver AI Summary
Revolution Medicines, Inc. and Summit Therapeutics, Inc. have announced a clinical collaboration to evaluate the safety and efficacy of Revolution Medicines' RAS(ON) inhibitors, including daraxonrasib, zoldonrasib, and elironrasib, in combination with Summit's ivonescimab, a bispecific antibody targeting PD-1/VEGF. The partnership aims to assess these combinations in treating RAS mutant cancers, specifically focusing on non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Both companies will retain commercial rights to their respective products, with Summit supplying ivonescimab and Revolution acting as the study sponsor. The collaboration seeks to enhance therapeutic outcomes for patients facing significant medical needs.
Potential Positives
- Revolution Medicines and Summit Therapeutics have entered a clinical collaboration to assess the safety and efficacy of multiple RAS(ON) inhibitors in combination with Summit's ivonescimab, potentially advancing treatments for RAS-addicted cancers.
- Promising initial evidence has been disclosed that indicates daraxonrasib and elironrasib can deliver additive antitumor activity when combined with a PD-1 antibody, enhancing their therapeutic potential.
- The collaboration targets three priority tumor types, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer, addressing significant unmet medical needs in oncology.
Potential Negatives
- The company is entering a clinical collaboration with a partner, which may indicate a lack of confidence in the efficacy of its therapies on their own.
- The forward-looking statements caution about substantial risks and uncertainties that could materially affect the company's development programs, casting doubt on the reliability of their future outcomes.
- The need for a partnership may signal limitations in the company’s resources or capabilities to progress its drug development independently.
FAQ
What is the focus of the clinical collaboration between Revolution Medicines and Summit Therapeutics?
The collaboration aims to evaluate the safety and efficacy of RAS(ON) inhibitors in combination with ivonescimab across multiple solid tumor types.
Which RAS(ON) inhibitors are being studied in this collaboration?
The study includes daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291).
What types of cancers will the clinical trials target?
The clinical trials will focus on RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer.
What are the expected benefits of combining RAS(ON) inhibitors with ivonescimab?
The combination is anticipated to improve treatment outcomes for patients with RAS-addicted cancers, enhancing antitumor activity.
How will the responsibilities be divided between the two companies?
Summit Therapeutics will supply ivonescimab while Revolution Medicines will act as the study sponsor, retaining commercial rights to their compounds.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RVMD Insider Trading Activity
$RVMD insiders have traded $RVMD stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:
- MARK A GOLDSMITH (See Remarks) has made 0 purchases and 2 sales selling 25,234 shares for an estimated $995,800.
- JEFF CISLINI (General Counsel) has made 0 purchases and 5 sales selling 9,695 shares for an estimated $383,908.
- STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 2 sales selling 7,583 shares for an estimated $299,429.
- MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 2 sales selling 6,568 shares for an estimated $259,188.
- JACK ANDERS (Chief Financial Officer) has made 0 purchases and 2 sales selling 4,034 shares for an estimated $159,202.
- LIN WEI (Chief Medical Officer) sold 2,173 shares for an estimated $86,550
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RVMD Hedge Fund Activity
We have seen 144 institutional investors add shares of $RVMD stock to their portfolio, and 150 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BOXER CAPITAL MANAGEMENT, LLC removed 2,961,487 shares (-69.2%) from their portfolio in Q1 2025, for an estimated $104,718,180
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,673,429 shares (+inf%) to their portfolio in Q1 2025, for an estimated $59,172,449
- LORD, ABBETT & CO. LLC removed 1,611,090 shares (-81.4%) from their portfolio in Q1 2025, for an estimated $56,968,142
- MARSHALL WACE, LLP removed 1,317,613 shares (-87.6%) from their portfolio in Q1 2025, for an estimated $46,590,795
- NEXTECH INVEST LTD. added 1,304,347 shares (+20.7%) to their portfolio in Q4 2024, for an estimated $57,052,137
- BALYASNY ASSET MANAGEMENT L.P. removed 1,302,848 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $46,068,705
- WESTFIELD CAPITAL MANAGEMENT CO LP added 1,058,247 shares (+18248.8%) to their portfolio in Q1 2025, for an estimated $37,419,613
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RVMD Analyst Ratings
Wall Street analysts have issued reports on $RVMD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 05/14/2025
- UBS issued a "Buy" rating on 01/08/2025
To track analyst ratings and price targets for $RVMD, check out Quiver Quantitative's $RVMD forecast page.
$RVMD Price Targets
Multiple analysts have issued price targets for $RVMD recently. We have seen 3 analysts offer price targets for $RVMD in the last 6 months, with a median target of $71.0.
Here are some recent targets:
- Robert Burns from H.C. Wainwright set a target price of $72.0 on 05/14/2025
- Benjamin Burnett from Stifel Nicolaus set a target price of $64.0 on 04/01/2025
- Eliana Merle from UBS set a target price of $71.0 on 01/08/2025
Full Release
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines’ clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics’ ivonescimab, a PD-1 / VEGF bispecific antibody.
“We’ve disclosed promising initial evidence that each of daraxonrasib and elironrasib can deliver additive antitumor activity safely when combined with a PD-1 antibody in first-line treatment of patients with RAS mutant non-small cell lung cancer,” said Mark A. Goldsmith, M.D., Ph.D., chairman and chief executive officer of Revolution Medicines. “Combinations with novel PD-1 bispecific inhibitors could unlock further therapeutic potential. We are eager to evaluate combinations of investigational drugs from our RAS(ON) inhibitor portfolio with ivonescimab, an advanced PD-1 / VEGF bispecific inhibitor with a differentiated profile, in a range of common RAS mutant cancers.”
The clinical collaboration aims to evaluate these combinations across three priority tumor types including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Under the terms of the agreement, Summit Therapeutics will supply ivonescimab for clinical research and Revolution Medicines will be the study sponsor. Each company will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive.
“We’re thrilled to partner with Revolution Medicines to evaluate in a clinical setting how our highly promising ivonescimab combined with their compelling RAS(ON) inhibitors could potentially improve outcomes for patients with lung and gastrointestinal cancers,” said Robert W. Duggan, Chairman and Co-Chief Executive Officer and Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “As we continue to rapidly advance the development of ivonescimab across non-small cell lung cancer and other solid tumors, we believe that it is critically important to combine ivonescimab with some of the most promising medicines and drug candidates as we seek to provide innovative therapy options to patients facing high unmet needs.”
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit
www.revmed.com
and follow us on
LinkedIn
.
About Summit Therapeutics, Inc.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Summit was founded in 2003 and its shares are listed on the Nasdaq Global Market (symbol “SMMT”). It is headquartered in Miami, Florida, and has additional offices in Menlo Park, California, and Oxford, UK.
For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.
Revolution Medicines Forward Looking Statements
This press release contains forward-looking statements regarding Revolution Medicines within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company’s candidates being studied and the durability of these results;
the ability of the company’s RAS(ON) inhibitors to deliver additive antitumor activity in combination with a PD-1 antibody or a PD-1 / VEGF bi-specific inhibitor and related therapeutic options; and the aims and plans of the clinical collaboration with Summit Therapeutics
. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Summit Forward-looking Statements
Any statements in this press release about the Summit Therapeutics’ future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Summit Therapeutics’ product candidates, entry into and actions related to the Summit Therapeutics’ partnership with Akeso Inc., the Summit Therapeutics' anticipated spending and cash runway, the therapeutic potential of the Summit Therapeutics’ product candidates, the potential commercialization of the Summit Therapeutics’ product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Summit Therapeutics’ ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Summit Therapeutics’ pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Summit Therapeutics’ foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Summit Therapeutics makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Summit Therapeutics’ views only as of the date of this release and should not be relied upon as representing the Summit Therapeutics’ views as of any subsequent date. The Summit Therapeutics specifically disclaims any obligation to update any forward-looking statements included in this press release.
Revolution Medicines Media & Investor Contact:
[email protected]
[email protected]
Summit Therapeutics’ Media & Investor Contact:
Dave Gancarz
Chief Business & Strategy Officer
Nathan LiaBraaten
Senior Director, Investor Relations
[email protected]
[email protected]